Satisfai Health, which provides medical solutions along with artificial intelligence (AI) applications, has licensed AI software from the University of Augsburg and the Technical University of Applied Sciences of Regensburg. With Satisfai’s AI technology, it will be possible to manage Barrett’s Esophagus effectively, including detecting esophageal cancer at its earliest stage when it is curable. Globally, around 150 million people suffer from Barrett’s disease.
Dr. Michael Byrne, Satisfai Health CEO, and Clinical Professor of Medicine in Vancouver said, “We are passionate about developing technology that helps doctors and their patients. Our collaborations and partnerships aim to deliver precision care to millions of patients across a range of GI diseases.”
Satisfai Health acquired AI-enhanced software to enable clinicians to diagnose endoscopic conditions more quickly and accurately. In the diagnosis process, the esophagus is imaged and biopsied to screen for precancerous cells (dysplasia) which can be treated to prevent cancer in the esophagus.
According to Dr. Helmut Messman, Professor of Gastroenterology at the University of Augsburg and current President of the European Society of Gastrointestinal Endoscopy (ESGE), “AI will revolutionize endoscopy and our tool is the first step to improve and optimize the detection of Barrett’s cancer. I am extremely happy that we will continue our research in this field with Satisfai.”
Dr. Christoph Palm, Professor of Medical Image Computing in Regensburg, said, “OTH Regensburg and University Hospital Augsburg unite several years of successful research in AI for the upper gastrointestinal tract. We are delighted to collaborate with Satisfai to translate this research into clinical practice.”
